(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of -10.71% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 133.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Ironwood Pharmaceuticals's revenue in 2025 is $338,987,000.On average, 7 Wall Street analysts forecast IRWD's revenue for 2025 to be $46,096,621,414, with the lowest IRWD revenue forecast at $43,285,534,394, and the highest IRWD revenue forecast at $50,305,118,012. On average, 7 Wall Street analysts forecast IRWD's revenue for 2026 to be $43,835,388,221, with the lowest IRWD revenue forecast at $35,997,531,008, and the highest IRWD revenue forecast at $51,398,318,520.
In 2027, IRWD is forecast to generate $38,603,642,933 in revenue, with the lowest revenue forecast at $28,537,088,257 and the highest revenue forecast at $48,904,454,861.